|
| Tuesday, October 15, 2019 |
|
|
Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China |
| Eisai Co., Ltd. has announced that Eisai received a New Drug Approval for its in-house discovered and developed antiepileptic drug (AED) Fycompa (perampanel) from the China National Medical Products Administration (NMPA) for use in an adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older. more info >> |
|
| Tuesday, October 1, 2019 |
|
|
Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress |
| The findings were presented in a proffered paper presentation at the European Society for Medical Oncology (ESMO) 2019 Congress (Abstract #994O). more info >> |
|
| Monday, September 30, 2019 |
|
|
Eisai and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceutical Business in China |
| Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China. more info >> |
|
| Thursday, September 26, 2019 |
|
|
Eisai and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence and Prevention of Dementia |
| Eisai Co., Ltd. and Tokio Marine & Nichido Fire Insurance Co., Ltd. announced today that the companies have entered into a business alliance agreement for co-existence and prevention of dementia. more info >> |
|
|
Eisai and Fronteo to Launch Coroban Tumbling and Falling Prediction System for Inpatients |
| Eisai Co., Ltd. and FRONTEO, Inc. announced today that they have launched the tumbling and falling prediction system Coroban to medical institutions in Japan on September 26, 2019. more info >> |
|
| Tuesday, September 24, 2019 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress |
| Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain, from September 27 to October 1, 2019. more info >> |
|
| Friday, September 20, 2019 |
|
|
Eisai and Meiji Announce Parkinson's Disease Treatment Equfina Tablets (Safinamide Mesilate) Approved In Japan |
| In Japan, Meiji holds the manufacturing and marketing approval for safinamide, and Eisai exclusively sells the safinamide. more info >> |
|
|
Eisai's Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India |
| Eisai Co., Ltd. has announced that Eisai's subsidiary Eisai Pharmaceuticals India Pvt. Ltd. and Mylan N. V. subsidiary Mylan India have entered into a license agreement to promote and distribute the second brand TECERIS for the anticancer agent eribulin mesylate (eribulin) in India. more info >> |
|
| Thursday, September 19, 2019 |
|
|
Eisai to Present Latest Data on Lemborexant at World Sleep Congress |
| Eisai Co., Ltd. has announced that latest data on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of sleep-wake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) associated with Alzheimer's disease/dementia will be presented at World Sleep Congress (World Sleep 2019), from September 20 to 25 in Vancouver, Canada. more info >> |
|
| Wednesday, September 18, 2019 |
|
|
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2019 |
| Eisai Co., Ltd. has been selected for a membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI). more info >> |
|
|
|
